PMID- 34960125
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211231
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 12
DP  - 2021 Nov 24
TI  - Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare 
      Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.
LID - 10.3390/vaccines9121379 [doi]
LID - 1379
AB  - The COVID-19 pandemic is changing rapidly and requires different strategies to 
      maintain immunization. In Korea, different COVID-19 vaccines are recommended and 
      available for various populations, including healthcare workers (HCWs) at high 
      risk of SARS-CoV-2 infection. We plan to evaluate the adverse events (AEs) and 
      immunogenicity of the BNT162b2 and ChAdOx1 vaccines in HCWs at a single center. 
      This cohort study included HCWs fully vaccinated with either BNT162b2 or ChAdOx1. 
      Blood samples were taken eight weeks after the second vaccination with both 
      COVID-19 vaccines and six months after the second vaccination from participants 
      with the BNT162b2 vaccine. The primary endpoint for immunogenicity was the serum 
      neutralizing antibody responses eight weeks after vaccination. The secondary 
      endpoint was the incidence of various AEs within 28 days of each vaccination. 
      Between 16 March and 23 June 2021, 115 participants were enrolled (65 in the 
      ChAdOx1 group and 50 in the BNT162b2 group). Significantly higher surrogate virus 
      neutralization test (sVNT) inhibition was observed in participants vaccinated 
      with two doses of BNT162b2 (mean (SD) 91.4 (9.68)%) than in those vaccinated with 
      ChAdOx1 (mean (SD) 73.3 (22.57)%). The effectiveness of the BNT162b2 vaccine was 
      maintained across all age and gender categories. At six months after the second 
      dose, serum antibody levels declined significantly in the BNT162b2 group. The 
      main adverse events, including fever, myalgia, fatigue, and headache, were 
      significantly higher in the ChAdOx1 group after the first dose, whereas, after 
      the second dose, those AEs were significantly higher in the BNT162b2 group (p < 
      0.05). Two doses of either the ChAdOx1 or the BNT162b2 COVID-19 vaccine resulted 
      in very high seropositivity among the HCWs at our center. The quality of the 
      antibody response, measured by sVNT inhibition, was significantly better with the 
      BNT162b2 vaccine than with the ChAdOx1 vaccine. There was no significant 
      association between neutralizing antibody response and AE after each vaccination 
      in our cohort.
FAU - Lim, Sung-Hee
AU  - Lim SH
AUID- ORCID: 0000-0003-0845-9994
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Choi, Seong-Hyeok
AU  - Choi SH
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Kim, Bora
AU  - Kim B
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Kim, Ji-Youn
AU  - Kim JY
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Ji, Young-Sok
AU  - Ji YS
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Kim, Se-Hyung
AU  - Kim SH
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Kim, Chan-Kyu
AU  - Kim CK
AUID- ORCID: 0000-0002-1517-9950
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Kim, Tark
AU  - Kim T
AD  - Department of Medicine, Division of Infectious Disease, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Choo, Eun-Ju
AU  - Choo EJ
AUID- ORCID: 0000-0003-2842-7041
AD  - Department of Medicine, Division of Infectious Disease, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Moon, Ji-Eun
AU  - Moon JE
AUID- ORCID: 0000-0002-7293-7463
AD  - Department of Biostatistics, Soonchunhyang University Bucheon Hospital, Bucheon 
      14584, Korea.
FAU - Yun, Jina
AU  - Yun J
AUID- ORCID: 0000-0001-5897-8309
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
FAU - Park, Seong-Kyu
AU  - Park SK
AD  - Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University 
      Bucheon Hospital, Bucheon 14584, Korea.
LA  - eng
PT  - Journal Article
DEP - 20211124
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8708890
OTO - NOTNLM
OT  - BNT162b2
OT  - ChAdOx1
OT  - SARS-CoV-2 vaccines
OT  - neutralizing antibodies immunogenicity
COIS- Authors declare no conflict of interest.
EDAT- 2021/12/29 06:00
MHDA- 2021/12/29 06:01
PMCR- 2021/11/24
CRDT- 2021/12/28 01:05
PHST- 2021/11/03 00:00 [received]
PHST- 2021/11/17 00:00 [revised]
PHST- 2021/11/21 00:00 [accepted]
PHST- 2021/12/28 01:05 [entrez]
PHST- 2021/12/29 06:00 [pubmed]
PHST- 2021/12/29 06:01 [medline]
PHST- 2021/11/24 00:00 [pmc-release]
AID - vaccines9121379 [pii]
AID - vaccines-09-01379 [pii]
AID - 10.3390/vaccines9121379 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 Nov 24;9(12):1379. doi: 10.3390/vaccines9121379.